Synthesizing the results of three previous studies, researchers from the Headache Care Center in Springfield, Missouri, concluded that one 2.5 mg dose of zolmitriptan (Zomig) may provide long-term relief from migraines.
The findings, which were presented at the Diamond Headache Clinic’s Headache Update `99, analyze the compiled data of three different studies. Each study compared groups of participants that took either zolmitriptan (Zomig) or a placebo, though no one knew which pill they were taking.
The studies show that migraines most often occur between six and seven in the morning when people are getting ready for work and school. Taking the medication between 6 and 9 a.m. provided headache relief for an average of 23 hours for those who responded to the medication. Participants who responded to the placebo had an average relief time lasting only eight hours.
Approximately 60 percent of those taking a single dose (2.5 mg) of zolmitriptan had a positive response within two hours of taking the drug, whereas only 22 to 39 percent of the people taking the placebo responded positively in that amount of time.
The researchers concluded that zolmitriptan (Zomig) does provide long-acting, reliable relief for migraine, despite the time of day the headache occurs.
The manufacturer suggests that the medication is appropriate to treat acute migraines in adults, either with or without an aura. It’s not recommended if you have hypertension, ischemic heart disease, or another significant type of heart condition.
Side effects include feelings of pain, pressure, and heaviness or tightness in various parts of the body, including the chest. Adverse effects that appeared during clinical trials ranged from mild to moderate, with the most prevalent being asthenia (weakness), dizziness, and nausea.